



## (51) International Patent Classification:

*A61P 35/00* (2006.01) *A61K 31/519* (2006.01)

63/545,531

24 October 2023 (24.10.2023) US

## (21) International Application Number:

PCT/US2023/080513

(71) Applicant: **TREELINE BIOSCIENCES, INC.** [US/US];  
677 Washington Blvd., Suite 525, Stamford, Connecticut  
06901 (US).

## (22) International Filing Date:

20 November 2023 (20.11.2023)

(72) Inventors: **CABRAL, Shawn**; 500 Arsenal Street, 2nd  
Floor, Watertown, Massachusetts 02472 (US). **MASCIT-  
TI, Vincent**; 500 Arsenal Street, 2nd Floor, Watertown,  
Massachusetts 02472 (US). **DECULTOT, Ludovic Jacky  
Gilbert**; 500 Arsenal Street, 2nd Floor, Watertown, Mass-  
achusetts 02472 (US). **HEROLD, Jens-Martin**; 500 Ar-  
senal Street, 2nd Floor, Watertown, Massachusetts 02472  
(US). **HESP, Kevin D.**; 500 Arsenal Street, 2nd Floor, Wa-  
tertown, Massachusetts 02472 (US). **LAJINESS, James  
Paul**; 11180 Roselle Street, Suite A, San Diego, Califor-  
nia 92121 (US). **SEIM, Alexander E.**; 500 Arsenal Street,  
2nd Floor, Watertown, Massachusetts 02472 (US). **TO-  
FOLEANU, Florentina**; 500 Arsenal Street, 2nd Floor,

## (25) Filing Language:

English








## (26) Publication Language:

English

## (30) Priority Data:

|            |                               |    |
|------------|-------------------------------|----|
| 63/426,950 | 21 November 2022 (21.11.2022) | US |
| 63/456,235 | 31 March 2023 (31.03.2023)    | US |
| 63/515,290 | 24 July 2023 (24.07.2023)     | US |
| 63/533,346 | 17 August 2023 (17.08.2023)   | US |
| 63/535,006 | 28 August 2023 (28.08.2023)   | US |
| 63/542,188 | 03 October 2023 (03.10.2023)  | US |

## (54) Title: SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS



(57) **Abstract:** This disclosure provides compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or pharmaceutically acceptable salts thereof, that inhibit a KRas protein. These compounds are useful, for example, for treating a disease, disorder, or condition in which increased and/or sustained KRas activation (e.g., KRas activation associated with a mutant KRas protein), contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. This disclosure also provides compositions containing the compounds provided herein, or pharmaceutically acceptable salts thereof.





Watertown, Massachusetts 02472 (US). **TSAI, Andy**; 500 Arsenal Street, 2nd Floor, Watertown, Massachusetts 02472 (US).

(74) **Agent: KENDALL, John T.** et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

**Published:**

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*